Patents by Inventor Emanuele Gabellieri

Emanuele Gabellieri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
    Publication number: 20200148679
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: January 9, 2020
    Publication date: May 14, 2020
    Inventors: Sreenivasachary NAMPALLY, Emanuele GABELLIERI, Jerome MOLETTE
  • COMPOUNDS FOR IMAGING TAU PROTEIN AGGREGATES
    Publication number: 20190262480
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 29, 2019
    Inventors: Heiko KROTH, Jérôme MOLETTE, Vicent DARMENCY, Hanno SCHIEFERSTEIN, Andre MÜLLER, Heribert SCHMITT-WILLICH, Mathias BERNDT, Felix ODEN, Emanuele GABELLIERI
  • Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
    Publication number: 20190211012
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: March 13, 2019
    Publication date: July 11, 2019
    Inventors: Sreenivasachary NAMPALLY, Emanuele GABELLIERI, Jerome MOLETTE
  • BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY
    Publication number: 20190071450
    Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (?-synuclein, A-synuclein, aSynuclein, A-syn, ?-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.
    Type: Application
    Filed: March 10, 2017
    Publication date: March 7, 2019
    Inventors: Jérôme MOLETTE, Emanuele GABELLIERI, Vincent DARMENCY
  • NOVEL IMAGING COMPOUNDS
    Publication number: 20180264146
    Abstract: The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 15, 2016
    Publication date: September 20, 2018
    Applicants: AC IMMUNE S.A., PIRAMAL IMAGING SA
    Inventors: Heiko KROTH, Sreenivasachary NAMPALLY, Jérôme MOLETTE, Emanuele GABELLIERI, Hanno SCHIEFERSTEIN, Andre MÜLLER, Heribert SCHMITT-WILLICH, Mathias BERNDT
  • S1P3 ANTAGONISTS
    Publication number: 20180201582
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 19, 2018
    Applicant: Teva Pharmaceutical Industries Limited
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • S1P3 antagonists
    Patent number: 9951017
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: April 24, 2018
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C Terstappen
  • Carbazole and Carboline Compounds for Use in the Diagnosis, Treatment, Alleviation or Prevention of Disorders Associated with Amyloid or Amyloid-Like Proteins
    Publication number: 20170002005
    Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Alzheimer's disease. Precursors for the preparation of the compounds according to the present invention are also provided.
    Type: Application
    Filed: January 21, 2015
    Publication date: January 5, 2017
    Inventors: Heiko KROTH, Sreenivasachary NAMPALLY, Jérôme MOLETTE, Emanuele GABELLIERI, Pascal André René BENDERITTER, Wolfgang FROESTL, Hanno SCHIEFERSTEIN, Andre MUELLER, Heribert SCHMITT-WILLICH, Mathias BERNDT
  • S1P3 ANTAGONISTS
    Publication number: 20160297762
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Application
    Filed: November 28, 2014
    Publication date: October 13, 2016
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • 1,4 oxazines as BACE1 and/or BACE2 inhibitors
    Patent number: 9242943
    Abstract: The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: January 26, 2016
    Assignees: SIENA BIOTECH S.P.A., HOFFMANN-LA ROCHE INC.
    Inventors: Matteo Andreini, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Alexander V. Mayweg, Robert Narquizian, Eoin Power, Massimiliano Travagli, Thomas Woltering, Wolfgang Wostl, Harald Mauser
  • 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS
    Publication number: 20140336208
    Abstract: This invention relates to compounds of the formula wherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.
    Type: Application
    Filed: July 9, 2014
    Publication date: November 13, 2014
    Inventors: David Banner, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Benoit Hornsperger, Roland Humm, Harald Mauser, Alexander V. Mayweg, Robert Narquizian, Emmanuel Pinard, Mark Rogers-Evans, Thomas Woltering, Wolfgang Wostl
  • 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
    Patent number: 8815881
    Abstract: This invention relates to compounds of the formula wherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: August 26, 2014
    Assignees: Hoffmann-La Roche Inc., Siena Biotech S.p.A.
    Inventors: David Banner, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Benoit Hornsperger, Roland Humm, Harald Mauser, Alexander V. Mayweg, Robert Narquizian, Emmanuel Pinard, Mark Rogers-Evans, Thomas Woltering, Wolfgang Wostl
  • 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
    Patent number: 8748418
    Abstract: The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: June 10, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Harald Mauser, Alexander V. Mayweg, Mark Rogers-Evans, Didier Rombach, Andrew Thomas, Thomas Woltering, Wolfgang Wostl
  • 1,4 oxazines as BACE1 and/or BACE2 inhibitors
    Patent number: 8399459
    Abstract: The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: March 19, 2013
    Assignees: Hoffmann-La Roche Inc., Siena Biotech SpA
    Inventors: Matteo Andreini, Emanuele Gabellieri, Robert Narquizian, Massimiliano Travagli, Wolfgang Wostl
  • 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS
    Publication number: 20120238548
    Abstract: The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 20, 2012
    Inventors: Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Harald Mauser, Alexander V. Mayweg, Mark Rogers-Evans, Didier Rombach, Andrew Thomas, Thomas Woltering, Wolfgang Wostl
  • 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES
    Publication number: 20120214806
    Abstract: The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Application
    Filed: May 1, 2012
    Publication date: August 23, 2012
    Inventors: Matteo Andreini, David Banner, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Harald Mauser, Alexander V. Mayweg, Robert Narquizian, Eoin Power, Mark Rogers-Evans, Massimiliano Travagli, Michela Valacchi, Thomas Woltering, Wolfgang Wostl
  • 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
    Publication number: 20120196863
    Abstract: The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 2, 2012
    Inventors: Matteo Andreini, Emanuele Gabellieri, Robert Narquizian, Massimiliano Travagli, Wolfgang Wostl
  • 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
    Publication number: 20120184540
    Abstract: The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Application
    Filed: January 12, 2012
    Publication date: July 19, 2012
    Inventors: Matteo Andreini, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Alexander V. Mayweg, Robert Narquizian, Eoin Power, Massimiliano Travagli, Thomas Woltering, Wolfgang Wostl, Harald Mauser
  • 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS
    Publication number: 20120035195
    Abstract: This invention relates to compounds of the formula wherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.
    Type: Application
    Filed: August 3, 2011
    Publication date: February 9, 2012
    Inventors: David Banner, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Benoit Hornsperger, Roland Humm, Harald Mauser, Alexander V. Mayweg, Robert Narquizian, Emmanuel Pinard, Mark Rogers-Evans, Thomas Woltering, Wolfgang Wostl
  • 4,5-dihydro-oxazol-2-yl amine derivatives
    Patent number: 7989449
    Abstract: The present invention relates to a compounds of formula I wherein R1, R1?, R2, R3, R4, X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (?-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: August 2, 2011
    Assignees: Hoffman-La Roche Inc., Siena Biotech S.p.A.
    Inventors: Matteo Andreini, Emanuele Gabellieri, Wolfgang Guba, Guido Marconi, Robert Narquizian, Eoin Power, Massimiliano Travagli, Thomas Woltering, Wolfgang Wostl